Nathalie Støer works within pharmacoepidemiology with projects that use registry links to either explore associations between drug use and the risk of cancer, or investigate whether commonly used drugs, used in combination with standard cancer treatment, can improve the prognosis of cancer patients. Støer holds a PhD in biostatistics from the University of Oslo. Before she started at the Cancer Registry of Norway in 2016, she was a postdoctoral fellow at Karolinska Institutet.
Nathalie works within pharmacoepidemiology with projects that use registry links to either explore associations between drug use and the risk of cancer, or investigate whether commonly used drugs, used in combination with standard cancer treatment, can improve the prognosis of cancer patients. In addition, a newly launched project is investigating the use of newer cancer drugs in the treatment of breast cancer patients.
Nathalie is also interested in late effects in young cancer survivors, both somatic, psychological and socioeconomic. In addition, Nathalie is involved in the Cervical Screening Programme, which is the Norwegian screening programme for cervical cancer.
Previously, Nathalie has worked extensively with epidemiological sampling designs and how to utilize the information from these as efficiently as possible.
Nathalie holds a PhD in biostatistics from the University of Oslo. Before she started at the Cancer Registry of Norway in 2016, she was a postdoctoral fellow at Karolinska Institutet.
β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.
Løfling LL, Støer NC, Sloan EK, Chang A, Gandini S, Ursin G, Botteri E.Br J Cancer. 2022 Jun 20. doi: 10.1038/s41416-022-01891-7. Online ahead of print.PMID: 35725814
Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway.
Støer NC, Bouche G, Pantziarka P, Sloan EK, Andreassen BK, Botteri E.Acta Oncol. 2021 Sep;60(9):1146-1153. doi: 10.1080/0284186X.2021.1953136. Epub 2021 Aug 2.PMID: 34338111
Drug Use and Cancer Risk: A Drug-Wide Association Study (DWAS) in Norway.
Støer NC, Botteri E, Thoresen GH, Karlstad Ø, Weiderpass E, Friis S, Pottegård A, Andreassen BK.Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):682-689. doi: 10.1158/1055-9965.EPI-20-1028. Epub 2020 Nov 3.PMID: 33144282
Metformin use and lung cancer survival: a population-based study in Norway.
Brancher S, Støer NC, Weiderpass E, Damhuis RAM, Johannesen TB, Botteri E, Strand TE.Br J Cancer. 2021 Mar;124(5):1018-1025. doi: 10.1038/s41416-020-01186-9. Epub 2020 Dec 2.PMID: 33262518
Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, Ursin G, Weiderpass E (2017)
Int J Cancer, 141 (9), 1763-1770
DOI 10.1002/ijc.30878, PubMed 28685818
Selected media clips
To millioner nordmenn med i ny registerstudie (Norwegian only) https://www.dagensmedisin.no/artikler/2020/12/10/kreft-to-millioner-nordmenn-med-i-ny-register-studie/ Dagensmedisin.no
Hormonbruk i overgangsalder og brystkreft: Hva er status i dag? (Norwegian only) https://blogg.forskning.no/kvinnehelsebloggen/hormonbruk-i-overgangsalderen-og-brystkreft-hva-er-status-i-dag/1596611
Kvinnehelsebloggen, forskning.no
